Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Taxes (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Current Taxes for 9 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 472.92% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 472.92% year-over-year, with the annual reading at $7.5 million for FY2025, 472.92% up from the prior year.
  • Current Taxes hit $7.5 million in Q4 2025 for Ascendis Pharma A, up from $1.3 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $7.5 million in Q4 2025 to a low of $226506.3 in Q4 2021.
  • Historically, Current Taxes has averaged $3.4 million across 5 years, with a median of $2.5 million in 2023.
  • Biggest five-year swings in Current Taxes: soared 2372.85% in 2022 and later crashed 55.84% in 2023.
  • Year by year, Current Taxes stood at $226506.3 in 2021, then skyrocketed by 2372.85% to $5.6 million in 2022, then plummeted by 55.84% to $2.5 million in 2023, then plummeted by 47.21% to $1.3 million in 2024, then surged by 472.92% to $7.5 million in 2025.
  • Business Quant data shows Current Taxes for ASND at $7.5 million in Q4 2025, $1.3 million in Q4 2024, and $2.5 million in Q4 2023.